Attovia Therapeutics Raises $105M Series B

Attovia Therapeutics, a Fremont, CA-based developer of a pipeline of biotherapeutics with an initial focus on immune-mediated diseases, raised $105m in Series B financing.

The round, which brought the total amount to $165m, was led by Goldman Sachs Alternatives, with participation from new investors Cormorant Asset Management, Nextech Ventures, Redmile Group, EcoR1 Capital, Marshall Wace, Logos Capital and existing investors Frazier Life Sciences, venBio, and Illumina Ventures. Concurrent with the financing, Colin Walsh, Ph.D., Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, was appointed to the Board of Directors.

The company intends to us the funds to advance its lead programs ATTO-1310 and ATTO-002 through initial clinical data readouts, expand its immunology and inflammation pipeline, and to further develop the ATTOBODY™ platform.

Led by CEO Tao Fu, Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. The lead programs, ATTO-1310, a potential first-in-class, long half-life anti-IL31 ATTOBODY, and ATTO-002, a bispecific anti-IL31 x IL13 ATTOBODY, represent potential best-in-class therapeutics for a range of immune-mediated diseases. ATTO-1310 is currently in IND enabling studies and is on track to enter the clinic around year-end 2024 for the treatment of atopic dermatitis and other pruritic diseases. Attovia expects to nominate a development candidate for ATTO-002 in the second half of 2024 and advance the candidate to IND in 2025. The company is also developing discovery stage programs that expand the ATTOBODY platform footprint to novel, difficult-to-drug targets, and offer additional multi-specific combinations.

Commenting on the news, Tao Fu said: “We are grateful for the support from such a strong group of investors, allowing us to advance our lead programs to the clinic in the near term, further expand our pipeline in novel bi-specifics, and catalyze potential business development opportunities.”